Alector Inc (ALEC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alector Inc (ALEC) has a cash flow conversion efficiency ratio of -1.360x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-41.69 Million) by net assets ($30.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Alector Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Alector Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Alector Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Alector Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alector Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Garuda Construction & Engineering
NSE:GARUDA
|
0.011x |
|
Cartesian Therapeutics Inc.
NASDAQ:RNAC
|
0.149x |
|
New World Resources Ltd
AU:NWC
|
-0.015x |
|
LIWANLI Innovation Co Ltd
TW:3054
|
-0.056x |
|
Hyosung Chemical Corp
KO:298000
|
-0.068x |
|
Group Eleven Resources Corp
V:ZNG
|
-0.080x |
|
Toro Ltd
NASDAQ:TORO
|
0.013x |
|
Kangstem Biotech Co. Ltd
KQ:217730
|
-0.056x |
Annual Cash Flow Conversion Efficiency for Alector Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Alector Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Alector Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $30.65 Million | $-184.03 Million | -6.004x | -231.17% |
| 2024-12-31 | $126.80 Million | $-229.91 Million | -1.813x | -32.08% |
| 2023-12-31 | $134.16 Million | $-184.16 Million | -1.373x | -1348.03% |
| 2022-12-31 | $214.44 Million | $-20.33 Million | -0.095x | -109.55% |
| 2021-12-31 | $300.72 Million | $298.55 Million | 0.993x | +259.29% |
| 2020-12-31 | $267.53 Million | $-166.73 Million | -0.623x | -22.22% |
| 2019-12-31 | $194.74 Million | $-99.31 Million | -0.510x | +61.03% |
| 2018-12-31 | $-97.40 Million | $127.46 Million | -1.309x | -483.18% |
| 2017-12-31 | $-52.03 Million | $-17.77 Million | 0.342x | -34.53% |
| 2016-12-31 | $-24.91 Million | $-12.99 Million | 0.522x | -- |
About Alector Inc
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheim… Read more